DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Post-Hims/Novo settlement + FDA enforcement environment. Calculate cost delta from your current compounded provider to Wegovy/Zepbound with 6-step transition plan.
Why switching matters now
Novo v Hims settlement (Mar 2026) + Lilly v Mochi suit (Apr 2026) + HHS→DOJ Empower referral (Feb 2026) + FDA 30-letter warning batch (Mar 2026) signal industry-wide pressure on compounded model. Service disruption risk grows through 2026. Most patients have viable insurance pathway — use this calculator to plan your transition.
1. Where are you now (compounded)?
2. Which path to branded (Wegovy)?
Switching SAVES you $2,088/year. The chosen branded path is cheaper than your current compounded option. Plus you get FDA-approved purity guarantees + insurance-backed safety net.
Compounded telehealth → branded requires non-compounding prescriber. PCP, endocrinologist, or obesity medicine specialist. Schedule appointment with current weight + treatment history.
BMI ≥30 (or ≥27 with comorbidity) qualifies for weight-loss indication (Wegovy/Zepbound). T2D diagnosis qualifies for diabetes indication (Ozempic/Mounjaro). Confirm criteria with prescriber.
Insurance PA forms: BMI documentation + 3-6 month lifestyle program records + comorbidity ICD-10 codes. Prescriber's office handles submission. Typical approval 5-10 business days.
Don't stop compounded until branded is in hand. Order branded supply, wait until shipment arrives + ready to administer, then transition (one week of overlap acceptable).
Compounded dose ≠ branded dose due to formulation differences. Match by titration stage: if you were on compounded 2.4mg semaglutide, start branded Wegovy at 1.7mg first week, escalate to 2.4mg if tolerated. Conservative.
Once branded supply confirmed working: cancel compounded. Check subscription terms — many require web cancellation, some still require phone. Document cancellation confirmation.
You\'re currently on compounded semaglutide. The FDA-approved equivalent for weight-loss indication is Wegovy.
If you have type 2 diabetes diagnosis, alternative is Ozempic (diabetes-indicated). Insurance approval typically easier.
All cost paths verified May 2026. Prices change quarterly — confirm specific pricing with the channel (NovoCare, LillyDirect, TrumpRx, Costco). Insurance copay assumes manufacturer savings card applied. Without savings card, expect $50-100/month copay range.
FDA enforcement environment shifted in 2026. Novo v Hims settlement (Mar 2026), Lilly v Mochi trademark suit (Apr 2026), HHS→DOJ Empower referral (Feb 2026), and FDA 30-letter warning batch (Mar 2026) all signal compounded GLP-1 model is under pressure. Service disruption risk increases through 2026. Switching to FDA-approved branded products protects supply continuity.
Not always. Compounded formulations may use different salt forms (acetate, citrate) and concentrations than FDA-approved branded versions. Start branded at 1 dose step lower than your current compounded dose. Example: compounded semaglutide 2.4mg → start Wegovy 1.7mg first week, escalate to 2.4mg next week if tolerated.
Depends on path. Insurance with PA + manufacturer savings card: ~$25/mo (LESS than compounded). Manufacturer cash-pay direct (NovoCare/LillyDirect): $499-549/mo (more than compounded). Government TrumpRx: $300-350/mo (slightly more). Use the calculator above for your specific scenario.
Most commercial plans cover with prior authorization. Requirements: BMI ≥30 (or ≥27 with comorbidity like hypertension, diabetes, sleep apnea), documented 3-6 month lifestyle program, age 18+. Your in-person prescriber handles PA submission. Typical approval 5-10 business days.
Several backup paths: (1) Appeal with additional documentation (most denials reverse on appeal), (2) NovoCare or LillyDirect cash-pay programs (~$500/month), (3) TrumpRx government rail ($300-350/month sliding to $245 by 2028), (4) Switch to T2D-indicated product (Ozempic/Mounjaro) if you qualify with diabetes diagnosis.
No — overlap is fine. Order branded supply first, wait until it arrives, then transition on next injection day. Don't stop compounded until branded is in hand to avoid treatment gap. One week of overlap won't cause issues.
No reset risk. Same active ingredient, same mechanism. Continuity of weight loss is preserved. Most patients experience smoother titration on branded due to formulation consistency. Side-effect profile may even improve (compounded variability sometimes causes inconsistent nausea).